Controversies in Neuro-Oncology

Avastin and Malignant Gliomas

Indexed in: Chemical Abstracts, EBSCO, Ulrich's Periodicals Directory.

Neuro-oncology is an embryonic field of cancer research with a number of clinical trials in progress. However, the prognosis on neuro-oncologic patients has remained poor. Moreover, several small ...
[view complete introduction]

US $

*(Excluding Mailing and Handling)

Avastin and Malignant Gliomas: Is there a Role?

Pp. 12-18 (7)

Teri N. Kreisl


Bevacizumab is the first new drug approved for malignant glioma in a decade and demonstrates the potential for antiangiogenic therapy in the management of these patients. It has demonstrated improved radiographic response and progression free survival rates compared to historical controls as monotherapy. Bevacizumab has also been shown to improve patient symptoms of disease and decrease steroid requirements contributing to improved quality of life for glioma patients. Optimal combinations with other standard and targeted therapies are under investigation, as well as new imaging techniques to evaluate response to therapy, motivated in part by concerns over suspected increase potential for tumor invasion.


Neuro-Oncology Branch - NCI, 9030 Old Georgetown Road, Bldg. 82, Rm. 243, Bethesda, MD 20892.